Chief Executive Officer and Chairman of the Board
Dr. Rodger Curren co-founded IIVS and currently serves as CEO and Chairman of the Board of Directors.
After more than 10 years of specializing in genetic toxicology and chemical carcinogenesis, Dr. Rodger D. Curren created an In Vitro Toxicology Division as part of the contract research organization Microbiological Associates (now BioReliance) in 1988. This activity was subsequently incorporated as its own non-profit Institute, the Institute for In Vitro Sciences, Inc. (IIVS) in 1997. The goal was — and still is — to provide educational and laboratory-based resources for non-animal safety testing to industry, government, and animal welfare organizations, as well as the general public.
In addition to Dr. Curren’s work with IIVS, he serves on many national and international committees and science advisory boards of organizations focused on the development, validation, and practical use of alternative methods to whole animal testing. Among other activities, he is past president of the American Society for Cellular and Computational Toxicology (ASCCT), and a former member of both the Scientific Advisory Committee for the European Center for the Validation of Alternative Methods (ECVAM) and the Scientific Advisory Committee for Alternative Toxicological Methods in the U.S. He currently serves on the Advisory Boards of the Center for Responsible Science and the International Foundation for Ethical Research.
Dr. Curren’s efforts in optimizing and promoting new alternative methods have earned him several honors in the in vitro field, including the Russell and Burch Award, the Bjorn Ekwall Memorial award, and the William and Eleanor Cave award for outstanding achievements in the development, validation and advancement of humane alternatives for product testing.
Dr. Curren received his B.S. (Biology) from Purdue University, followed by an M.S. from Ohio University and a Ph.D. in microbial genetics from the Institute of Microbiology at Rutgers University. His post-doctoral work (human cell mutagenesis and DNA repair) was conducted at the Michigan Cancer Foundation and Michigan State University.